Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00769223 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started1993-02-25
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 192 months later Jan 31, 2026 → Jan 31, 2042
See other at-risk trials from University of California, San Francisco

Amendment history

2026-09-09
Study Status, Study Description v16
Primary completion pushed: 2026-01-31 → 2042-01-31
Completion pushed: 2026-01-31 → 2042-01-31
2025-03-19
Study Status v15
Primary completion date2025-01-31→2026-01-31
Completion date2025-01-31→2026-01-31
2023-12-15
3 amendments v12-v14
3 re-verifications since 2021-12-06, no change to tracked fields
2020-12-02
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v11
Trial statusRecruiting→Active, Not Recruiting
Start date1993-02-01→1993-02-25
Enrollment targetestimated 3500→confirmed 3561
Study sitesdetails revised at 1 of 1 site
2020-04-06
Study Identification, Study Status, Sponsor/Collaborators, Oversight, Outcome Measures, Eligibility, Contacts/Locations, IPDSharing v10
Primary completion date2020-12→2025-01-31
Completion date2021-06→2025-01-31
Start date1993-02→1993-02-01
Eligibility criteria+42 characters
[...] hormonal therapy for adenocarcinoma of the prostate in the University of California, San Francisco (UCSF) Radiation Oncology Department at San Francisco General Hosp [...]
Study sites1 entry, revised
UCSFUniversity Helenof DillerCalifornia, FamilySan Comprehensive Cancer CenterFrancisco
Collaborators-31 characters
National Cancer Institute (NCI)
Show 9 earlier versions
2018-04-30
Study Status, Study Design, Eligibility v9
Re-verified, no change to tracked fields
2014-10-13
Study Identification, Study Status, Oversight, Outcome Measures, Eligibility v8
Completion datenot stated→2021-06
Study title-64 characters
Gleason Score, Prostate-Specific Antigen Level, and Cancer Stage in Predicting Outcomethe Risk of Failure in Patients Who Have UndergoneUndergoing Radiation Therapy for Localized Prostate Cancer
2014-01-23
Study Identification, Study Status, Sponsor/Collaborators, Study Design, Eligibility v7
Primary completion date2013-02→2020-12
2011-02-18
2 amendments v5-v6
2 re-verifications since 2009-05-09, no change to tracked fields
2009-02-06
Study Status, Arms and Interventions v4
Interventionsbrachytherapy (Procedure), medical chart review (Procedure), quality-of-life assessment (Procedure), questionnaire administration…→brachytherapy (Radiation), medical chart review (Other), quality-of-life assessment (Procedure), questionnaire administration (Other)…
2009-01-21
3 amendments v1-v3
3 re-verifications since 2008-10-18, no change to tracked fields
2008-10-08
Original filing
RATIONALE: Gathering information about the Gleason score, prostate-specific antigen (PSA) level, and cancer stage from patients who have undergone radiation therapy for prostate cancer may help doctors predict how patients respond to treatment and help plan the best treatment. PURPOSE: This clinical trial is studying the Gleason score, PSA level, and cancer stage in predicting outcome in patients who have undergone radiation therapy for localized prostate cancer.
Trial Details
NCT Number NCT00769223
Lead Sponsor University of California, San Francisco
Conditions Prostate Cancer, Radiation Toxicity
Enrollment 3,561 participants
Start Date 1993-02-25
Primary Completion 2042-01-31 (estimated)
Study Completion 2042-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-09-14